Home/Filings/4/0001213900-25-028231
4//SEC Filing

Chell Jeffrey W. 4

Accession 0001213900-25-028231

CIK 0001388320other

Filed

Apr 1, 8:00 PM ET

Accepted

Apr 2, 6:22 PM ET

Size

19.0 KB

Accession

0001213900-25-028231

Insider Transaction Report

Form 4
Period: 2025-03-31
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-318,3330 total
    Exercise: $9.55Exp: 2030-08-12Common Stock (8,333 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-3118,3510 total
    Exercise: $6.07Exp: 2031-09-01Common Stock (18,351 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-3172,1560 total
    Exercise: $4.96Exp: 2032-07-01Common Stock (72,156 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-312,5000 total
    Exercise: $10.41Exp: 2028-04-27Common Stock (2,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-318,3330 total
    Exercise: $6.96Exp: 2029-07-12Common Stock (8,333 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-3170,3110 total
    Exercise: $5.00Exp: 2033-12-28Common Stock (70,311 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-03-312,5000 total
    Exercise: $23.49Exp: 2028-07-13Common Stock (2,500 underlying)
Footnotes (1)
  • [F1]Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration.

Issuer

Actinium Pharmaceuticals, Inc.

CIK 0001388320

Entity typeother

Related Parties

1
  • filerCIK 0001738374

Filing Metadata

Form type
4
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 6:22 PM ET
Size
19.0 KB